Prediction of liver injury induced by chemicals in human with a multiparametric assay on isolated mouse liver mitochondria

Toxicological Sciences

Volumn 129, Issue 2, 2012, Pages 332-345

  Porceddu, Mathieu ^a   Buron, Nelly ^a   Roussel, Célestin ^a   Labbe, Gilles ^b   Fromenty, Bernard ^c   Borgne Sanchez, Annie ^a  

^a HÔpital Robert Debré   (France)

^b SANOFI   (France)

^c INSERM   (France)

Author keywords

Chemicals; DILI; Drugs; Hepatotoxicity; Mitochondria; Prediction; Screening

Indexed keywords

ACETYLSALICYLIC ACID; ALPIDEM; AMIODARONE; DEXAMETHASONE; DICLOFENAC; DOXORUBICIN; ERLOTINIB; GEFITINIB; GENTAMICIN; IBUPROFEN; IMATINIB; LUMIRACOXIB; MEFENAMIC ACID; METFORMIN; NILOTINIB; PARACETAMOL; PERHEXILINE MALEATE; PIROXICAM; PRAVASTATIN; PYRAZINAMIDE; RANITIDINE; RIFAMPICIN; SAQUINAVIR; SIMVASTATIN; TICLOPIDINE; TRAMADOL; TROGLITAZONE; UNINDEXED DRUG; VALPROIC ACID; ZIDOVUDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASSAY; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; FEMALE; HIGH THROUGHPUT SCREENING; LIVER MITOCHONDRION; MEMBRANE PERMEABILITY; MITOCHONDRIAL MEMBRANE; MITOCHONDRIAL RESPIRATION; MOUSE; MULTIPARAMETRIC ASSAY; NONHUMAN; PROTEIN SECRETION; TOXIC HEPATITIS;

ANIMALS; DRUG-INDUCED LIVER INJURY; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; MICE, INBRED BALB C; MITOCHONDRIA, LIVER;

ANIMALIA;

EID: 84866596506     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfs197     Document Type: Article

References (49)

1. Begriche, K., Massart, J., Robin, M. A., Borgne-Sanchez, A., and Fromenty, B. (2011). Drug-induced toxicity on mitochondria and lipid metabolism: Mechanistic diversity and deleterious consequences for the liver. J. Hepatol. 54, 773-794.
2. Berson, A., De Beco, V., Lettéron, P., Robin, M. A., Moreau, C., El Kahwaji, J., Verthier, N., Feldmann, G., Fromenty, B., and Pessayre, D. (1998). Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. Gastroenterology 114, 764-774.
3. Berson, A., Descatoire, V., Sutton, A., Fau, D., Maulny, B., Vadrot, N., Feldmann, G., Berthon, B., Tordjmann, T., and Pessayre, D. (2001). Toxicity of alpidem, a peripheral benzodiazepine receptor ligand, but not zolpidem, in rat hepatocytes: Role of mitochondrial permeability transition and metabolic activation. J. Pharmacol. Exp. Ther. 299, 793-800.
4. Biour, M., Ben Salem, C., Chazouilléres, O., Grangé J. D., Serfaty, L., and Poupon, R. (2004). Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs. Gastroenterol. Clin. Biol. 28, 720-759.
5. Björnsson, E. (2009). The natural history of drug-induced liver injury. Semin. Liver Dis. 29, 357-363.
6. Boelsterli, U. A., and Lim, P. L. (2007). Mitochondrial abnormalities-a link to idiosyncratic drug hepatotoxicity? Toxicol. Appl. Pharmacol. 220, 92-107.
7. Boelsterli, U. A., and Hsiao, C. J. (2008). The heterozygous Sod2(+/-) mouse: Modeling the mitochondrial role in drug toxicity. Drug Discov. Today 13, 982-988.
8. Brauchli, Y. B., Wais, T., Gratwohl, A., Heim, D., Schipf, A., Diebold, J., and Krähenbühl, S. (2010). Fatal myocardial infarction during nilotinib treatment in a 60-year-old male patient. Acta Oncol. 49, 523-525.
9. Buron, N., Porceddu, M., Brabant, M., Desgué D., Racoeur, C., Lassalle, M., Péchoux, C., Rustin, P., Jacotot, E., and Borgne-Sanchez, A. (2010). Use of human cancer cell lines mitochondria to explore the mechanisms of BH3 peptides and ABT-737-induced mitochondrial membrane permeabilization. PLOS ONE 5, e9924.
10. Deschamps, D., DeBeco, V., Fisch, C., Fromenty, B., Guillouzo, A., and Pessayre, D. (1994). Inhibition by perhexiline of oxidative phosphorylation and the beta-oxidation of fatty acids: Possible role in pseudoalcoholic liver lesions. Hepatology 19, 948-961.
11. Dykens, J. A., Jamieson, J. D., Marroquin, L. D., Nadanaciva, S., Xu, J. J., Dunn, M. C., Smith, A. R., and Will, Y. (2008). In vitro assessment of mitochondrial dysfunction and cytotoxicity of nefazodone, trazodone, and buspirone. Toxicol. Sci. 103, 335-345.
12. Dykens, J. A., and Will, Y. (2007). The significance of mitochondrial toxicity testing in drug development. Drug Discov. Today 12, 777-785.
13. Fromenty, B., and Pessayre, D. (1995). Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity. Pharmacol. Ther. 67, 101-154.
14. Gougeon, M. L., Pénicaud, L., Fromenty, B., Leclercq, P., Viard, J. P., and Capeau, J. (2004). Adipocytes targets and actors in the pathogenesis of HIV-associated lipodystrophy and metabolic alterations. Antivir. Ther. (Lond.) 9, 161-177.
15. Greaves, P., Williams, A., and Eve, M. (2004). First dose of potential new medicines to humans: How animals help. Nat. Rev. Drug Discov. 3, 226-236.
16. Höpfner, M., Sutter, A. P., Huether, A., Schuppan, D., Zeitz, M., and Scherübl, H. (2004). Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma. J. Hepatol. 41, 1008-1016.
17. Igoudjil, A. B. K., Pessayre, D., and Fromenty, B. (2006). Mitochondrial, metabolic and genotoxic effects of antiretroviral nucleoside reverse-transcriptase inhibitors. Anti-Infective Agents Med. Chem. 5, 273-292.
18. Jiang, B., Hebert, V. Y., Li, Y., Mathis, J. M., Alexander, J. S., and Dugas, T. R. (2007). HIV antiretroviral drug combination induces endothelial mitochondrial dysfunction and reactive oxygen species production, but not apoptosis. Toxicol. Appl. Pharmacol. 224, 60-71.
19. Jordani, M. C., Santos, A. C., Prado, I. M., Uyemura, S. A., and Curti, C. (2000). Flufenamic acid as an inducer of mitochondrial permeability transition. Mol. Cell Biochem. 210, 153-158.
20. Kamel, A., Colizza, K., Gunduz, M., Harriman, S., and Obach, R. S. (2012). In vitro-in vivo correlation for intrinsic clearance for CP-409,092 and sumatriptan: A case study to predict the in vivo clearance for compounds metabolized by monoamine oxidase. Xenobiotica 42, 355-362.
21. Kennedy, J. A., Unger, S. A., and Horowitz, J. D. (1996). Inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone. Biochem. Pharmacol. 52, 273-280.
22. Kerkela, R., Woulfe, K. C., Durand, J. B., Vagnozzi, R., Kramer, D., Chu, T. F., Beahm, C., Chen, M. H., and Force, T. (2009). Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase. Clin. Transl. Sci. 2, 15-25.
23. Labbe, G., Pessayre, D., and Fromenty, B. (2008). Drug-induced liver injury through mitochondrial dysfunction: Mechanisms and detection during preclinical safety studies. Fundam. Clin. Pharmacol. 22, 335-353.
24. Larrey, D. (2000). Drug-induced liver diseases. J. Hepatol. 32, 77-88.
25. Lebrecht, D., Venhoff, A. C., Kirschner, J., Wiech, T., Venhoff, N., and Walker, U. A. (2009). Mitochondrial tubulopathy in tenofovir disoproxil fumarate-treated rats. J. Acquir. Immune Defic. Syndr. 51, 258-263.
26. Lecoeur, H., Langonné A., Baux, L., Rebouillat, D., Rustin, P., Prévost, M. C., Brenner, C., Edelman, L., and Jacotot, E. (2004). Real-time flow cytometry analysis of permeability transition in isolated mitochondria. Exp. Cell Res. 294, 106-117.
27. Lee, W. M. (2003). Drug-induced hepatotoxicity. N. Engl. J. Med. 349, 474-485.
28. Li, Y., Qi, X. M., Xue, X., Wu, X. F., Wu, Y. F., Chen, M., Xing, G. Z., Luan, Y., and Ren, J. (2009). The relationship between diphenylamine structure and NSAIDs-induced hepatocytes injury. Toxicol. Lett. 186, 111-114.
29. Masubuchi, Y., Kano, S., and Horie, T. (2006). Mitochondrial permeability transition as a potential determinant of hepatotoxicity of antidiabetic thiazolidinediones. Toxicology 222, 233-239.
30. Masubuchi, Y., Nakayama, S., and Horie, T. (2002). Role of mitochondrial permeability transition in diclofenac-induced hepatocyte injury in rats. Hepatology 35, 544-551.
31. Masubuchi, Y., Suda, C., and Horie, T. (2005). Involvement of mitochondrial permeability transition in acetaminophen-induced liver injury in mice. J. Hepatol. 42, 110-116.
32. McDougall, P., Markham, A., Cameron, I., and Sweetman, A. J. (1983). The mechanism of inhibition of mitochondrial oxidative phosphorylation by the nonsteroidal anti-inflammatory agent diflunisal. Biochem. Pharmacol. 32, 2595-2598.
33. Nakagawa, Y., and Moore, G. (1999). Role of mitochondrial membrane permeability transition in p-hydroxybenzoate ester-induced cytotoxicity in rat hepatocytes. Biochem. Pharmacol. 58, 811-816.
34. Okuda, T., Norioka, M., Shitara, Y., and Horie, T. (2010). Multiple mechanisms underlying troglitazone-induced mitochondrial permeability transition. Toxicol. Appl. Pharmacol. 248, 242-248.
35. Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., et al. (2000). Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul. Toxicol. Pharmacol. 32, 56-67.
36. Orphanos, G. S., Ioannidis, G. N., and Ardavanis, A. G. (2009). Cardiotoxicity induced by tyrosine kinase inhibitors. Acta Oncol. 48, 964-970.
37. Ostapowicz, G., Fontana, R. J., Schiødt, F. V., Larson, A., Davern, T. J., Han, S. H., McCashland, T. M., Shakil, A. O., Hay, J. E., Hynan, L., et al. (2002). Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann. Intern. Med. 137, 947-954.
38. Pellicoro, A., and Faber, K. N. (2007). Review article: The function and regulation of proteins involved in bile salt biosynthesis and transport. Aliment. Pharmacol. Ther. 26(Suppl. 2), 149-160.
39. Pessayre, D., Mansouri, A., Berson, A., and Fromenty, B. (2010). Mitochondrial involvement in drug-induced liver injury. Handb. Exp. Pharmacol. 196, 311-365.
40. Rachek, L. I., Yuzefovych, L. V., Ledoux, S. P., Julie, N. L., and Wilson, G. L. (2009). Troglitazone, but not rosiglitazone, damages mitochondrial DNA and induces mitochondrial dysfunction and cell death in human hepatocytes. Toxicol. Appl. Pharmacol. 240, 348-354.
41. Robin, M. A., Anandatheerthavarada, H. K., Biswas, G., Sepuri, N. B., Gordon, D. M., Pain, D., and Avadhani, N. G. (2002). Bimodal targeting of microsomal CYP2E1 to mitochondria through activation of an N-terminal chimeric signal by cAMP-mediated phosphorylation. J. Biol. Chem. 277, 40583-40593.
42. Russmann, S., Kullak-Ublick, G. A., and Grattagliano, I. (2009). Current concepts of mechanisms in drug-induced hepatotoxicity. Curr. Med. Chem. 16, 3041-3053.
43. Stirnimann, G., Kessebohm, K., and Lauterburg, B. (2010). Liver injury caused by drugs: An update. Swiss Med. Wkly. 140, w13080.
44. Scatena, R., Bottoni, P., Botta, G., Martorana, G. E., and Giardina, B. (2007). The role of mitochondria in pharmacotoxicology: A reevaluation of an old, newly emerging topic. Am. J. Physiol. 293, C12-C21.
45. Stewart, J. D., Horvath, R., Baruffini, E., Ferrero, I., Bulst, S., Watkins, P. B., Fontana, R. J., Day, C. P., and Chinnery, P. F. (2010). Polymerase γ gene POLG determines the risk of sodium valproate-induced liver toxicity. Hepatology 52, 1791-1796.
46. Viengchareun, S., Caron, M., Auclair, M., Kim, M. J., Frachon, P., Capeau, J., Lombés, M., and Lombés, A. (2007). Mitochondrial toxicity of indinavir, stavudine and zidovudine involves multiple cellular targets in white and brown adipocytes. Antivir. Ther. (Lond.) 12, 919-929.
47. Vo, T. T., Yoo, Y. M., Choi, K. C., and Jeung, E. B. (2010). Potential estrogenic effect(s) of parabens at the prepubertal stage of a postnatal female rat model. Reprod. Toxicol. 29, 306-316.
48. Will, Y., Dykens, J. A., Nadanaciva, S., Hirakawa, B., Jamieson, J., Marroquin, L. D., Hynes, J., Patyna, S., and Jessen, B. A. (2008). Effect of the multi-targeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells. Toxicol. Sci. 106, 153-161.
49. Will, Y., Hynes, J., Ogurtsov, V. I., and Papkovsky, D. B. (2006). Analysis of mitochondrial function using phosphorescent oxygen-sensitive probes. Nat. Protoc. 1, 2563-2572.